MTA2 as a Potential Biomarker and Its Involvement in Metastatic Progression of Human Renal Cancer by miR-133b Targeting MMP-9

Metastasis-associated protein 2 (MTA2) was previously known as a requirement to maintain malignant potentials in several human cancers. However, the role of MTA2 in the progression of renal cell carcinoma (RCC) has not yet been delineated. In this study, MTA2 expression was significantly increased i...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2019-11, Vol.11 (12), p.1851
Main Authors: Chen, Yong-Syuan, Hung, Tung-Wei, Su, Shih-Chi, Lin, Chia-Liang, Yang, Shun-Fa, Lee, Chu-Che, Yeh, Chang-Fang, Hsieh, Yi-Hsien, Tsai, Jen-Pi
Format: Article
Language:English
Subjects:
3' Untranslated regions
Biomarkers
Breast cancer
Cell cycle
Cell growth
Cell proliferation
Gelatinase B
Gene expression
Genomes
Growth factors
Invasiveness
Kinases
Matrix metalloproteinase
Medical prognosis
Metalloproteinase
Metastases
Metastasis
MicroRNAs
Molecular modelling
Polymerase chain reaction
Proteins
Renal cell carcinoma
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metastasis-associated protein 2 (MTA2) was previously known as a requirement to maintain malignant potentials in several human cancers. However, the role of MTA2 in the progression of renal cell carcinoma (RCC) has not yet been delineated. In this study, MTA2 expression was significantly increased in RCC tissues and cell lines. Increased MTA2 expression was significantly associated with tumour grade ( = 0.002) and was an independent prognostic factor for overall survival with a high RCC tumour grade. MTA2 knockdown inhibited the migration, invasion, and in vivo metastasis of RCC cells without effects on cell proliferation. Regarding molecular mechanisms, MTA2 knockdown reduced the activity, protein level, and mRNA expression of matrix metalloproteinase-9 (MMP-9) in RCC cells. Further analyses demonstrated that patients with lower miR-133b expression had poorer survival rates than those with higher expression from The Cancer Genome Atlas database. Moreover, miR-133b modulated the 3'untranslated region (UTR) of MMP-9 promoter activities and subsequently the migratory and invasive abilities of these dysregulated expressions of MTA2 in RCC cells. The inhibition of MTA2 could contribute to human RCC metastasis by regulating the expression of miR-133b targeting MMP-9 expression.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers11121851